Skip to main content
Research

Publications: Dr Monica Calado Marta

Allen-Philbey K, Stennett A, Begum T, Johnson AC, MacDougall A, Green S, Dobson R, Giovannoni G et al. ( 2022 ) . Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 65 ,
Anderson V, Bentley E, Loveless S, Bianchi L, Harding KE, Thomas RW, Giovannoni G, Robertson NP et al. ( 2022 ) . 058 Serum neurofilament-light concentration and real-world outcome in MS . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a30.3 - a3a31 .
Giovannoni G, Hobart J, Mazibrada G, Bateman K, Marta M ( 2022 ) . 125 Towards an optimal multiple sclerosis patient case-load for a full-time MSologist . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a140.1 - a1a140 .
Allen-Philbey K, Trane SD, Yildiz O, Adams A, Turner B, Marta M, Mathews J, Altmann D et al. ( 2022 ) . Personalised immunotherapy in active multiple sclerosis using injectable cladrib- ine: Follow-up of the BartsMS cohort . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a2.3 - a2a2 .
Dobson R ( 2022 ) . Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS) . Multiple Sclerosis and Related Disorders
Rodgers J, Friede T, Vonberg FW, Constantinescu CS, Coles A, Chataway J, Duddy M, Emsley H et al. ( 2022 ) . The impact of smoking cessation on multiple sclerosis disease progression . Brain vol. 145 , ( 4 ) 1368 - 1378 .
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2022 ) . Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study . Multiple Sclerosis and Related Disorders vol. 57 ,
Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Webb S, Hemingway C, Hobart J et al. ( 2021 ) . Optimise: MS study protocol: A pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis . BMJ Open vol. 11 , ( 11 )
Chan TYH, De Zan V, Gregg A, Alagaratnam J, Gerevini S, Antinori A, D'Arminio Monforte A, Saracino A et al. ( 2021 ) . The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series . AIDS (London, England) vol. 35 , ( 14 ) 2341 - 2346 .
Marta M, Baker D, Creeke P, Pryce G, Gnanapavan S, Giovannoni G ( 2021 ) . Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report . Multiple Sclerosis and Related Disorders vol. 56 ,
Allen-Philbey K, De Trane S, Mao Z, Álvarez-González C, Mathews J, MacDougall A, Stennett A, Zhou X et al. ( 2021 ) . Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients . Therapeutic Advances in Neurological Disorders vol. 14 ,
Stennett A, Allen-Philbey K, Begum T, Johnson A, Dobson R, Giovannoni G, Gnanapavan S, Marta M et al. ( 2021 ) . An evaluation of remote monitoring in people with MS during the COVID-19 pandemic . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 268 - 269 .
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2021 ) . Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 514 - 515 .
Rodgers WJ, Friede T, Vonberg FW, Constantinescu CS, Coles A, Chataway J, Emsley H, Ford H et al. ( 2021 ) . The impact of smoking cessation on multiple sclerosis disease progression . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 41 - 42 .
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Up to 6 years follow-up of people with MS (n=250) receiving cladribine . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 546 - 547 .
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 90 - 91 .
Smets I, Holden D, Bianchi L, Ammoscato F, Turner B, Marta M, Schmierer K, Giovannoni G et al. ( 2021 ) . Treatment-Induced Reductions in Cerebrospinal Fluid Neurofilament Light Levels are Age-Dependent in Multiple Sclerosis . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 27 - 28 .
Dobson R, ALLEN-PHILBEY K, Giovannoni G, Baker D, Schmierer K ( 2021 ) . Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis . Multiple Sclerosis and Related Disorders
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2020 ) . Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 522 - 523 .
Reyes S, Smets I, Holden D, Carrillo-Loza K, Christmas T, Bianchi L, Ammoscato F, Turner B et al. ( 2020 ) . CSF neurofilament light chain testing as an aid to determine treatment strategies in MS . Neurology(R) neuroimmunology & neuroinflammation vol. 7 , ( 6 )
Anderson V, Bentley E, Loveless S, Bianchi L, Harding KE, Wynford-Thomas RA, Joseph F, Giovannoni G et al. ( 2020 ) . Serum neurofilament-light concentration and real-world outcome in MS . Journal of the Neurological Sciences vol. 417 ,
Chan T, Marta M, Hawkins C, Rackstraw S ( 2020 ) . Cognitive and Neurologic Rehabilitation Strategies for Central Nervous System HIV Infection . Current HIV/AIDS Reports vol. 17 , ( 5 ) 514 - 521 .
Schmierer K, Gnanapavan S, Giovannoni G, Ammoscato F, Holden D, Carrillo-Loza K, Christmas T, Bianchi L et al. ( 2020 ) . CSF neurofilament light chain testing as an aid to determine treatment strategies in MS . Neurology, Neuroimmunology and Neuroinflammation vol. 7 , ( 6 )
Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G et al. ( 2020 ) . COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases . Clinical and Experimental Immunology vol. 202 , ( 2 ) 149 - 161 .
Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C, Mathews J, Lambourne J et al. ( 2020 ) . Protecting people with multiple sclerosis through vaccination . Practical Neurology
Krysko KM, Graves JS, Dobson R, Altintas A, Amato MP, Bernard J, Bonavita S, Bove R et al. ( 2020 ) . Sex effects across the lifespan in women with multiple sclerosis . Therapeutic Advances in Neurological Disorders vol. 13 ,
Baker D, Pryce G, James LK, Marta M, Schmierer K ( 2020 ) . The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis . Multiple Sclerosis and Related Disorders Article 102279 , 102279 - 102279 .
Smets I, Reyes S, Carrillo-Loza K, Mateo-Casas M, Bianchi L, Holden D, Ammoscato F, Turner B et al. ( 2020 ) . CSF Neurofilament Light Chain for guiding individual treatment decisions in multiple sclerosis . EUROPEAN JOURNAL OF NEUROLOGY . vol. 27 , 475 - 476 .
Reyes S, Suarez S, Allen-Philbey K, Yildiz Ö, Mathews J, Anjorin G, Edwards F, Jain C et al. ( 2020 ) . Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 41 ,
Baker D, Pryce G, James LK, Marta M, Schmierer K ( 2020 ) . The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis . Multiple Sclerosis and Related Disorders2020.01.09.20016774 - 2020.01.09.20016774 .
Middleton R, Lacey A, Pickrell W, Fonferfko-Shadrach B, Pearson O, Marta M, McDonnell G, Thompson et al. ( 2019 ) . 030 Automating clinical audit in neurology . Journal of Neurology Neurosurgery & Psychiatry . vol. 90 ,
Reyes S, Allen-Philbey K, Suarez S, Yildiz Ö, Turner B, Gnanapavan S, Schmierer K, Marta M et al. ( 2019 ) . 192 Does socioeconomic status impact on the prescription of disease-modifying treatments in people with multiple sclerosis? . Journal of Neurology Neurosurgery & Psychiatry . vol. 90 ,
De Trane S, Allen-Philbey K, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2019 ) . Cladribine at all stages of MS: two-year follow-up in 154 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 519 - 520 .
Reyes S, Carrillo-Loza K, Mateo M, Bianchi L, Holden D, Ammoscato F, Marta M, Turner B et al. ( 2019 ) . Evidence of the utility of CSF neurofilament light chain measurements in people with MS in clinical practice . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 854 - 854 .
Bianchi L, Baker D, Giovannoni G, Marta M ( 2019 ) . Neurofilament light chain levels in cerebrospinal fluid and serum of a longitudinal cohort of people with multiple sclerosis on disease modifying drugs . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 734 - 735 .
Marta M, Bianchi L, Lieberman D, Ciccarelli O, Collorone S, Kapoor R, Chataway J, Schmierer K et al. ( 2019 ) . Oxcarbazepine as a neuroprotective agent in MS: a phase IIa trial (PROXIMUS) . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 91 - 91 .
Lieberman DR, Giovannoni G, Cafferty F, Bianchi L, Gnanapavan S, Marta M, Altmann DR, Kapoor R ( 2019 ) . Seamless phase II-III adaptive trial design elements for progressive MS: Neurofilament light chain (phase II/interim endpoint), phase III endpoints and patient populations . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 600 - 600 .
De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner B et al. ( 2019 ) . Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in > 200 patients . NEUROLOGY . vol. 92 ,
Carrillo-Loza K, Reyes S, Bianchi L, Holden D, Espasandin M, Ammoscato F, Turner B, Schmierer K et al. ( 2019 ) . Real life Evidence for CSF Neurofilaments Light Chain in Clinical Practice . NEUROLOGY . vol. 92 ,
DOBSON R ( 2019 ) . Visibility and representation of women in multiple sclerosis research . Neurology
Marta M ( 2019 ) . No evidence of disease activity in people with multiple sclerosis . Eur J Neurol vol. 26 , ( 1 ) 1 - 2 .
Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2019 ) . Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies . Multiple Sclerosis and Related Disorders vol. 27 , 247 - 253 .
Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Thomson A, Schmierer K, Giovannoni G ( 2018 ) . Inclusion criteria used in trials of people with progressive multiple sclerosis . Mult Scler1352458518803769 - 1352458518803769 .
De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2018 ) . Cladribine personalised dosing in people with MS (n > 200) - four years experience in clinical care .
Gold J, Marta M, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al. ( 2018 ) . A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study . Multiple Sclerosis and Related Disorders vol. 24 , 123 - 128 .
Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G et al. ( 2018 ) . Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings? . Multiple Sclerosis Journal - Experimental, Translational and Clinical vol. 4 , ( 2 ) 2055217318783767 - 2055217318783767 .
Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S et al. ( 2018 ) . Alemtuzumab depletion failure can occur in multiple sclerosis . Immunology vol. 154 , ( 2 ) 253 - 260 .
Mao Z, Alvarez-Gonzalez C, Yildiz O, Allen-Philbey K, Turner B, Gnananpavan S, Marta M, Mathews J et al. ( 2018 ) . Personalised dosing of cladribine for people with multiple sclerosis . NEUROLOGY . vol. 90 ,
Reyes S, Allen-Philbey K, Suarez S, Yildiz O, Turner B, Gnanapavan S, Schmierer K, Marta M et al. ( 2018 ) . The Impact of Socioeconomic Status on Treatment Choice in Patients with Multiple Sclerosis . NEUROLOGY . vol. 90 ,
Rackstraw S, Marta M ( 2018 ) . Clinical presentation and treatment of patients with neurosymptomatic HIV cerebrospinal fluid escape . HIV MEDICINE . vol. 19 , S74 - S75 .
Dubuisson N, Baker D, Thomson A, Marta M, Gnanapavan S, Turner B, Giovannoni G, Schmierer K ( 2017 ) . Disease modification in advanced MS: Focus on upper limb function . Multiple Sclerosis vol. 23 , ( 14 ) 1956 - 1957 .
Dubuisson N, Bauer A, Marta M, Gnanapavan S, Turner B, Baker D, Giovannoni G, Schmierer K et al. ( 2017 ) . PO124 Validation of an environmentally-friendly and affordable cardboard 9-hole peg test . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 ,
Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Gnanapavan S, Marta M, Baker D et al. ( 2017 ) . PO134 Personalised dosing of cladribine to treat multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 ,
Schmierer K, Marta M, Pryce G, Giovannoni G, Baker D ( 2017 ) . PO150 Memory b cells are key for immunotherapy in multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 , a52 - a52 .
Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Turner B, Gnanapavan S, Marta M, Mathews J, Giovannoni G et al. ( 2017 ) . Cladribine personalised dosing to treat multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . vol. 23 , 609 - 609 .
Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Schmierer K, Giovannoni G ( 2017 ) . Identification of main inclusion criteria of chronic progressive multiple sclerosis clinical trials: a review . MULTIPLE SCLEROSIS JOURNAL . vol. 23 , 939 - 940 .
Dubuisson N, Bauer A, Buckley M, Gilbert R, Paterson A, Marta M, Gnanapavan S, Turner B et al. ( 2017 ) . Validation of an environmentally-friendly and affordable cardboard 9-hole peg test . Multiple Sclerosis and Related Disorders vol. 17 , 172 - 176 .
Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K ( 2017 ) . Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis . EBioMedicine vol. 16 , 41 - 50 .
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Baker D, Gnanapavan S, Marta M, Giovannoni G et al. ( 2016 ) . TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 87 ,
Thomson A, Giovannoni G, Marta M, Gnanpavan S, Turner B, Baker D, Schmierer K ( 2016 ) . Importance of upper limb function in advanced multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 676 - 676 .
Gold J, Marta MC, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al. ( 2016 ) . Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 188 - 189 .
Marta M, MacManus D, Yousry T, Miller D, Altmann DR, Meier UC, Christensen T, Maruszak H et al. ( 2016 ) . Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 188 - 188 .
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Espasandin M, Turner BP, Gnanapavan S, Marta M, Giovannoni G et al. ( 2016 ) . Treating multiple sclerosis with generic cladribine . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) vol. 22 , 604 - 605 .
Samoes R, Rackstraw S, Marta M ( 2016 ) . HIV-PML: remember to test . EUROPEAN JOURNAL OF NEUROLOGY . vol. 23 , 795 - 795 .
Williams T, Marta M, Giovannoni G ( 2016 ) . IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension . Practical Neurology vol. 16 , ( 3 ) 235 - 239 .
Giovannoni G, Marta M, Davis A, Turner B, Gnanapavan S, Schmierer K ( 2016 ) . Switching patients at high risk of PML from natalizumab to another disease-modifying therapy . Practical Neurologypractneurol-2015-001 - practneurol-2015-001 .
Martins J, Santos E, Salgado P, Maia L, Dias D, Marta M, França M ( 2016 ) . Recurrent cerebrospinal fluid escape in an HIV-1-infected patient receiving antiretroviral therapy . AIDS vol. 30 , ( 7 ) 1143 - 1144 .
Gold J, Giovannoni G, Marta MC, Meier U, Miller D, Christensen T, Maruszak H, Holden D et al. ( 2015 ) . Pilot baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study . MULTIPLE SCLEROSIS JOURNAL . vol. 21 , 162 - 162 .
Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M ( 2015 ) . Is it time to target no evident disease activity (NEDA) in multiple sclerosis? . Multiple Sclerosis and Related Disorders vol. 4 , ( 4 ) 329 - 333 .
Marta M, Santos E, Coutinho E, Silva AM, Correia J, Vasconcelos C, Giovannoni G ( 2015 ) . The role of infections in Behçet disease and neuro-Behçet syndrome . Autoimmunity Reviews vol. 14 , ( 7 ) 609 - 615 .
Tong CYW, Costelloe S, Hubb J, Mullen J, O'Shea S, Marta M, Kulasegaram R, Rackstraw S ( 2015 ) . Deep Sequencing of HIV-1 in Cerebrospinal Fluid . Clinical Infectious Diseases vol. 61 , ( 6 ) 1022 - 1025 .
Martins J, Salgado P, Santos E, Marta M, Franca M ( 2015 ) . CSF escape in an HIV-infected patient receiving antiretroviral therapy . EUROPEAN JOURNAL OF NEUROLOGY . vol. 22 , 511 - 511 .
Umaipalan A, Rackstraw S, Marta M ( 2015 ) . Prevalence of neurological disease at a joint HIV neurology clinic in East London . HIV MEDICINE . vol. 16 , 45 - 45 .
Marques IB, Flanagan S, Noble H, Giovannoni G, Marta M ( 2015 ) . Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse . Neurology: Neuroimmunology and NeuroInflammation vol. 2 , ( 2 )
Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC et al. ( 2015 ) . Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study . Multiple Sclerosis Journal vol. 21 , ( 8 ) 1013 - 1024 .
Fine D, Dattani A, Moreira I, Giovannoni G, Marta M ( 2015 ) . Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways? . Multiple Sclerosis and Related Disorders vol. 4 , ( 1 ) 88 - 91 .
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D et al. ( 2015 ) . No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine . Neurology: Neuroimmunology and NeuroInflammation vol. 2 , ( 6 )
Marques IB, Giovannoni G, Marta M ( 2014 ) . Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept . BMC Neurology vol. 14 , ( 1 )
Castelo-Branco G, Stridh P, Guerreiro-Cacais AO, Adzemovic MZ, Falcão AM, Marta M, Berglund R, Gillett A et al. ( 2014 ) . Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats . Neurobiol Dis vol. 71 , 220 - 233 .
Fine D, Dattani A, Moreira I, Giovannoni G, Marta M ( 2014 ) . Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways? . Multiple Sclerosis and Related Disorders
Schmierer K, Marta M, Turner B, Giovannoni G ( 2014 ) . THE USE OF MAGNETIC RESONANCE IMAGING (MRI) IN THE MANAGEMENT OF MULTIPLE SCLEROSIS IN THE UK . Journal of Neurology Neurosurgery & Psychiatry . vol. 85 , e4 - e4 .
Marta IMM ( 2014 ) . New and Old Concepts and Strategies for Progressive Multifocal Leukoencephalopathy . Journal of Multiple Sclerosis vol. 02 , ( 01 )
Flytzani S, Stridh P, Guerreiro-Cacais AO, Marta M, Hedreul MT, Jagodic M, Olsson T ( 2013 ) . Anti-MOG antibodies are under polygenic regulation with the most significant control coming from the C-type lectin-like gene locus . Genes Immun vol. 14 , ( 7 ) 409 - 419 .
Gnanapavan S, Grant D, Morant S, Furby J, Hayton T, Teunissen CE, Leoni V, Marta M et al. ( 2013 ) . Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS - Neurofilament as a Surrogate of Disease Progression . PLOS ONE vol. 8 , ( 8 ) Article ARTN e70019 ,
CALADO MARTA MS, Papachatzaki MM ( 2012 ) . Treatment issues in multiple sclerosis . Multiple Sclerosis Visual Guide for Clinicians , Editors: Giovannoni, G, Dobson, R , Hodder Christian Books
CALADO MARTA MS, giovannoni ( 2012 ) . ‘What does it mean to have MS? - chapter . Multiple Sclerosis , Oxford University Press ( United Kingdom ),
Marta M, Giovannoni G ( 2012 ) . Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon . CNS Neurol Disord Drug Targets vol. 11 , ( 5 ) 610 - 623 .
Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D, Melamud L, Marta M et al. ( 2012 ) . Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients . Neurology vol. 78 , ( 20 ) 1601 - 1607 .
Farrell RA, Marta M, Gaeguta AJ, Souslova V, Giovannoni G, Creeke PI ( 2012 ) . Development of resistance to biologic therapies with reference to IFN-β . Rheumatology (Oxford) vol. 51 , ( 4 ) 590 - 599 .
Dobson R, Meier UC, Marta M, Ramagopalan S, Giovannoni G ( 2011 ) . Vitamin D deficiency - do we follow our own advice? . CLINICAL MEDICINE vol. 11 , ( 6 ) 521 - 523 .
Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D et al. ( 2011 ) . A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS . Neurology vol. 77 , ( 16 ) 1551 - 1560 .
Jurgen F, Valerio M, Roberto R, Paolo SG, Marta M ( 2011 ) . 2-DE proteomic analysis of HSP70 in mollusc Chamelea gallina . Fish Shellfish Immunol vol. 30 , ( 2 ) 739 - 743 .
Maghzi A-H, Marta M, Bosca I, Etemadifar M, Dobson R, Maggiore C, Giovannoni G, Meier U-C ( 2011 ) . Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection? . Pathophysiology vol. 18 , ( 1 ) 13 - 20 .
Maghzi AH, Marta M, Bosca I, Savoj MR, Etemadifar M, Giovannoni G, Meier UC ( 2011 ) . Epstein–Barr Virus and Multiple Sclerosis: Wrong Place, Wrong Time? . Neuroinflammation , Editors: Minagar, A , Elsevier
Marta M, Santos E, Coutinho E, da Silva AM, Correia J, Vasconcelos C, Giovannoni G ( 2011 ) . INCREASED SERUM IL-8 LEVELS IN BEHCET DISEASE THAN NEUROBEHCET SYNDROME . CLIN EXP RHEUMATOL . vol. 29 , 173 - 173 .
Marta M, Santos E, Coutinho E, da Silva AM, Correia J, Vasconcelos C, Giovannoni G ( 2011 ) . VIRAL INFECTIONS IN NEUROBEHCET SYNDROME . CLIN EXP RHEUMATOL . vol. 29 , 193 - 194 .
Maghzi A-H, Marta M, Bosca I, Savoj M-R, Etemadifar M, Giovannoni G, Meier U-C ( 2010 ) . 2 Epstein–Barr Virus and Multiple Sclerosis Wrong Place, Wrong Time? . Neuroinflammation ,
Maghzi AH, Marta M, Bosca I, Savoj MR, Etemadifar M, Giovannoni G, Meier UC ( 2010 ) . Epstein–Barr Virus and Multiple Sclerosis: Wrong Place, Wrong Time? . Elsevier
Marta M ( 2010 ) . Gene regulation and immune mechanisms in multiple sclerosis experimental models . Supervisors: Olsson, T , Presented at: Karolinska Institutet ,
Stridh P, Thessen Hedreul M, Beyeen AD, Adzemovic MZ, Laaksonen H, Gillett A, Ockinger J, Marta M et al. ( 2010 ) . Fine-mapping resolves Eae23 into two QTLs and implicates ZEB1 as a candidate gene regulating experimental neuroinflammation in rat . PLoS One vol. 5 , ( 9 )
Gillett A, Marta M, Jin T, Tuncel J, Leclerc P, Nohra R, Lange S, Holmdahl R et al. ( 2010 ) . TNF production in macrophages is genetically determined and regulates inflammatory disease in rats . J Immunol vol. 185 , ( 1 ) 442 - 450 .
Marta M, Stridh P, Becanovic K, Gillett A, Ockinger J, Lorentzen JC, Jagodic M, Olsson T ( 2010 ) . Multiple loci comprising immune-related genes regulate experimental neuroinflammation . Genes Immun vol. 11 , ( 1 ) 21 - 36 .
Maghzi AH, Meier U, Holden D, Marta M, Kantor A, Waubant E, Giovannoni G, Goelz S ( 2009 ) . Natural killer cell status in multiple sclerosis and its association with interferon beta-1a treatment . MULTIPLE SCLEROSIS . vol. 15 , S73 - S73 .
Marta M ( 2009 ) . Toll-like receptors in multiple sclerosis mouse experimental models . Ann N Y Acad Sci vol. 1173 , 458 - 462 .
Marta M, Meier UC, Lobell A ( 2009 ) . Regulation of autoimmune encephalomyelitis by toll-like receptors . Autoimmun Rev vol. 8 , ( 6 ) 506 - 509 .
Huberle A, Beyeen AD, Ockinger J, Ayturan M, Jagodic M, de Graaf KL, Fissolo N, Marta M et al. ( 2009 ) . Advanced Intercross Line Mapping Suggests That Ncf1 (Ean6) Regulates Severity in an Animal Model of Guillain-Barre Syndrome . J IMMUNOL vol. 182 , ( 7 ) 4432 - 4438 .
Gillett AM, Marta M, Olsson T, Harris R, Jagodic M ( 2009 ) . Genetic potential of macrophage TNF production regulates immune mediated diseases . JOURNAL OF IMMUNOLOGY vol. 182 ,
Maggiore C, Meier UC, Marta M, Nissim A, Giovannoni G ( 2009 ) . B Cells and EBV Infection in People with MS . NEUROLOGY . vol. 72 , A37 - A37 .
Guo JP, Backdahl L, Marta M, Mathsson L, Ronnelid J, Lorentzen JC ( 2008 ) . Profound and paradoxical impact on arthritis and autoimmunity of the rat antigen-presenting lectin-like receptor complex . ARTHRITIS RHEUM vol. 58 , ( 5 ) 1343 - 1353 .
Marta M, Andersson A, Isaksson M, Kampe O, Lobell A ( 2008 ) . Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis . EUR J IMMUNOL vol. 38 , ( 2 ) 565 - 575 .
Silva AM, Pereira C, Bettencourt A, Carvalho C, Couto AR, Leite MI, Marta M, Freijo M et al. ( 2007 ) . The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population . J NEUROL SCI vol. 258 , ( 1-2 ) 69 - 74 .
Maia LF, Marta M, Lopes V, Rocha N, Lopes C, Martins-da-Silva A, Monteiro L ( 2006 ) . Hypersomnia in Whipple disease - Case report . ARQ NEURO-PSIQUIAT vol. 64 , ( 3B ) 865 - 868 .
Marta M, Andersson A, Isaksson M, Lobell A ( 2006 ) . Unexpected regulatory roles of TLR4 and TLR9 in an animal model for multiple sclerosis . JOURNAL OF NEUROIMMUNOLOGY . vol. 178 , 105 - 105 .
Sheng JR, Jagodic M, Dahlman I, Becanovic K, Nohra R, Marta M, Iacobaeus E, Olsson T et al. ( 2005 ) . Eae19, a new locus on rat chromosome 15 regulating experimental autoimmune encephalomyelitis . GENETICS vol. 170 , ( 1 ) 283 - 289 .
Roxburgh RHSR, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C et al. ( 2005 ) . Multiple sclerosis severity score - Using disability and disease duration to rate disease severity . NEUROLOGY vol. 64 , ( 7 ) 1144 - 1151 .
Jagodic M, Marta M, Becanovic K, Sheng JR, Nohra R, Olsson T, Lorentzen JC ( 2005 ) . Resolution of a 16.8-mb autoimmunity-regulating rat chromosome 4 region into multiple encephalomyrelitis quantitative trait loci and evidence for epistasis . J IMMUNOL vol. 174 , ( 2 ) 918 - 924 .
Olsson T, Wallstrom E, Jagodic M, Becanovic K, Marta M, Lidman O, Swanberg M, Piehl F ( 2004 ) . High resolution gene mapping of rat neuroinflammation . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 8 - 8 .
Marta M, Jagodic M, Olsson T, Lorentzen JC ( 2004 ) . High-resolution mapping of quantitative trait loci that influence an experimental model for multiple sclerosis in the rat . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 23 - 23 .
Sheng JR, Jagodic M, Dahlman I, Becanovic K, Nohra R, Marta M, Iacobaeus E, Olsson T et al. ( 2004 ) . Specially designed congenic rats on chromosome 15 provide a powerful tools for unravelling the genetic and immunological factors involved in the development of MOG-induced EAE . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 23 - 23 .
Khademi M, Illes Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, Brundin L, Hannerz J et al. ( 2004 ) . TIM-3 and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 104 - 104 .
Khademi M, Illés Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, Brundin L, Hannerz J et al. ( 2004 ) . T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis . J Immunol vol. 172 , ( 11 ) 7169 - 7176 .
Pedroso S, Correia J, Marta M, Barros R, De La Peña Moral J, Miranda H, Reis A, Rocha N ( 2004 ) . Autoimune hepatitis in patient with sclerosis without interferon therapy. A case report . Arquivos de Medicina vol. 18 , ( 1-2 )
Silva BM, Thorlacius T, Benediktsson K, Pereira C, Fossdal R, Jonsson HH, Silva A, Leite I et al. ( 2003 ) . A whole genome association study in multiple sclerosis patients from north Portugal . J NEUROIMMUNOL vol. 143 , ( 1-2 ) 116 - 119 .
Marta M, Palmares MC, Sousa A, Coelho T ( 2002 ) . Advantages of facioscapulohumeral muscular dystrophy molecular diagnosis: Experience with 13 families from the north of Portugal . JOURNAL OF THE NEUROLOGICAL SCIENCES . vol. 199 , S18 - S18 .
Marta M, Coelho T, Guimaraes A, Santos M ( 2002 ) . Autossomal recessive centronuclear myopathy: Clinical and muscle biopsy characteristics of three patients . JOURNAL OF THE NEUROLOGICAL SCIENCES . vol. 199 , S18 - S19 .
Silva AM, Marta M, Lemos J, Brito R, Leite I, Paiva I, Lopes J, Correia M et al. ( 2002 ) . Evoked Potentials in chronic idiopathic inflammatory demyelinating polyneuropathy . JOURNAL OF THE NEUROLOGICAL SCIENCES . vol. 199 , S40 - S40 .
Marta M, Silva AM, Silva AP, Meireles L, Coelho T, Leite I ( 2002 ) . Hearing loss in 17 patients with mitochondrial disorders . JOURNAL OF THE NEUROLOGICAL SCIENCES . vol. 199 , S71 - S71 .
Sousa A, Silva AM, Marta M, Sequeiros J, Coelho T ( 2001 ) . Familial amyloid neuropathy (FAP Met30) in Portugal: a combined use of family studies and a 60 years' register in the assessment of anticipation of age-at-onset and of the evolutionary dynamics of the gene . AM J HUM GENET vol. 69 , ( 4 ) 422 - 422 .
Silva AM, Marta M, Sousa A, Coelho T ( 2001 ) . Familial amyloid polyneuropathy in Portugal is a disease in expansion with variable age of onset . NEUROLOGY . vol. 56 , A326 - A326 .